Global ETD Search

Die Auswirkungen von Elexacaftor–Tezacaftor–Ivacaftor auf neutrophile Granulozyten, Monozyten und Thrombozyten bei Patientinnen und Patienten mit Cystischer Fibrose

Höpfer, Larissa MelinaUniversität Ulm

ulm-diss Repository record for Die Auswirkungen von Elexacaftor–Tezacaftor–Ivacaftor auf neutrophile Granulozyten, Monozyten und Thrombozyten bei Patientinnen und Patienten mit Cystischer Fibrose (opens in a new tab)

An investigation of the cellular effects of novel agents and multi-drug combinations in cystic fibrosis

Bani Melhim, SuhadQueen's University Belfast2022

… azithromycin (AZ). Given the emergence of elexacaftor/tezacaftor/ivacaftor (ETI), which is expected to restore CFTR activity in 90% of the CF population. The aim of this part of the study was to examine the effect of AZ and ETI, singly and in combination, to assess potential …

qu-belfast Repository record for An investigation of the cellular effects of novel agents and multi-drug combinations in cystic fibrosis (opens in a new tab)

Cystic fibrosis in South Africa: spectrum of disease, diagnosis, and determinants of outcome

Zampoli, MarcoDepartment of Paediatrics and Child Health2023

… one copy of F508del and are, thus, eligible for elexacaftor/tezacaftor/ivacaftor. A key finding of the registry-based studies was that lung function and nutrition outcomes in SA were significantly lower across all ages compared with Canada, attributed to differences in the quality of CF care and …

cape-town Repository record for Cystic fibrosis in South Africa: spectrum of disease, diagnosis, and determinants of outcome (opens in a new tab)